SQZ Biotechnologies Company
SQZ was delisted on the 3rd of July, 2023.
36 hedge funds and large institutions have $9.35M invested in SQZ Biotechnologies Company in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 13 closing their positions.
25% less funds holding
Funds holding: 48 → 36 (-12)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
72% less capital invested
Capital invested by funds: $33.5M → $9.35M (-$24.1M)
77% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 13
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stifel Financial
St. Louis,
Missouri
|
+$1.19M |
| 2 |
Renaissance Technologies
New York
|
+$121K |
| 3 |
Jane Street
New York
|
+$93.7K |
| 4 |
AMG
Advisors Management Group
La Crosse,
Wisconsin
|
+$30.6K |
| 5 |
HF
HRT Financial
New York
|
+$28.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$2M |
| 2 |
BlackRock
New York
|
-$341K |
| 3 |
E
Ergoteles
New York
|
-$75.9K |
| 4 |
DWM
Dakota Wealth Management
Palm Beach Gardens,
Florida
|
-$46K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$40K |
SQZ Hedge Fund Activity: Q4 2022 in Review
36 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in SQZ Biotechnologies Company (SQZ) for Q4 2022, worth a combined $9.35M — down 72% from $33.5M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of SQZ and 3 opened new positions — a net loss of 10 holders — while 9 trimmed existing stakes and 5 added.
The largest buyer was Stifel Financial, adding an estimated $1.19M. The largest seller was 683 Capital Management, cutting an estimated $2M.
- 36 institutional investors held SQZ Biotechnologies Company (SQZ) as of Q4 2022, down from 48 in Q3 2022.
- Funds reported $9.35M of SQZ Biotechnologies Company stock for Q4 2022, down 72% quarter-over-quarter.
- 3 funds opened new SQZ Biotechnologies Company positions in Q4 2022 and 13 closed out, a net change of -10 holders.
- The largest SQZ Biotechnologies Company buyer in Q4 2022 was Stifel Financial, an estimated $1.19M added.
- The largest SQZ Biotechnologies Company seller in Q4 2022 was 683 Capital Management, an estimated $2M sold.
Based on aggregated 13F filings for Q4 2022.